Clinical Trial Update: Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a CD5-targeted CAR-NK cell therapy for relapsed/refractory T-cell hematologic malignancies (T-ALL and T-cell lymphoma). Recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoma

Drugs mentioned

• CD5-targeted CAR-NK therapy (CD5-targeted chimeric antigen receptor natural killer cells)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: T-ALL/Lymphoma | Phase 1 | Status: RECRUITING